Page 5 - Graphite Bio News Today

Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.

Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have earned an average rating of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 1-year price target among analysts […]

/PRNewswire/ -- DelveInsights Sickle Cell Disease Market Insights report includes a comprehensive understanding of current treatment practices, sickle cell...

According to DelveInsight's estimates, the sickle cell disease market size in the 7MM is expected to show positive growth, during the forecast period (2023-2032), mainly attributed to the increasing

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities research analysts at Cantor Fitzgerald decreased their FY2023 earnings estimates for shares of Graphite Bio in a research note issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings of ($0.99) per share for the year, down from […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for Graphite Bio in a research report issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings per share of ($0.99) for the year, down from […]

Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single...

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML... | May 10, 2023

Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year price target among […]

In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.